Kymera Investor Presentation Deck

Response and Stable Disease Observed Across Multiple Tumor Types During Dose Escalation of KT-333 Tumor Type CTCL PTCL LGL-L CHL Solid Tumors # With ≥ 1 Assessment LO KYMERA ©2023 KYMERA THERAPEUTICS, INC. 1 2 1 12 Best Response 2 PR 1 SD 2 PD 1 PD Not Evaluable 1 PR 4 SD* 8 PD *Mucoepidermoid carcinoma of parotid gland (C7+), sinonasal adenocarcinoma (C5), cholangiocarcinoma (C3), renal cell cancer (C3+) Dose Level DL2+4 DL4 DL1+5 DL2 DL5 DL4 DL3+4 DL1-5 Summary: Disease control in 3 of 5 CTCL patients including 2 PR's and 1 SD; 1 PR in cHL, demonstrating single agent activity in liquid tumors supported by preclinical data In solid tumors, where preclinically no strong single agent activity was observed, a pattern of more prolonged SD in H&N tumors was seen with overall 4 patients with SD PAGE 29

View entire presentation